Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.

@article{Sochorov2009ParicalcitolD,
  title={Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.},
  author={Kl{\'a}ra Sochorov{\'a} and V{\'i}t Bud{\'i}nsk{\'y} and Daniela Ro{\vz}kov{\'a} and Zuzana Tobi{\'a}sov{\'a} and Sylvie Dusilov{\'a}-Sulkov{\'a} and Radek {\vS}p{\'i}{\vs}ek and Jiřina Bartůňkov{\'a}},
  journal={Clinical immunology},
  year={2009},
  volume={133 1},
  pages={69-77}
}
Paricalcitol (19-nor-1,25/OH(2)/D(2)), a second generation vitamin D receptor (VDR) activator, is a synthetic analogue of vitamin D3. In contrast to calcitriol, paricalcitol has a reduced effect on intestinal calcium resorption thus avoiding undesirable hypercalcemia. Information about immunomodulatory activity of paricalcitol is scarce. In this study we show that, in all investigated aspects, paricalcitol retains significant immunomodulatory activity, comparable to calcitriol. Both VDR… CONTINUE READING
32 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

Similar Papers

Loading similar papers…